

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

| | |
|---|--|
| Statement of Discontinuation of the study | |
| Name of Company: GlaxoSmithKline Biologicals | |
| Study No: 116763 (EudraCT# 2013-001918-15) | |
| Product: SB208109 | |
| Title: A phase IV, open-label, single-centre study to assess the long-term persistence of hepatitis A antibodies in healthy adults, primed 21 to 25 years earlier with GSK Biologicals' hepatitis A vaccine Havrix (SB208109) in studies HAV-112 (208109/108) or HAV-123 (208109/114). | |
| Phase: IV | |
| Study Period: May 2015 to July 2019 | |
| Centres: NA | |
| Number of Subjects: 0 | |
| Publications: NA | |
| Statement on discontinuation of the study: Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available. | |